The in vivo Down syndrome genomic library in mouse

Progress in Brain Research

Volumn 197, Issue , 2012, Pages 169-197

  Herault, Yann ^a,b,c   Duchon, Arnaud ^a   Velot, Emilie ^a   Maréchal, Damien ^a   Brault, Véronique ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b CNRS   (France)

^c INSTITUT CLINIQUE DE LA SOURIS   (France)

Author keywords

Genetic dosage; Learning; Locomotion; Memory; Trisomy 21

Indexed keywords

6 PHOSPHOFRUCTOKINASE; AMYLOID PRECURSOR PROTEIN; BRAIN PROTEIN; COPPER ZINC SUPEROXIDE DISMUTASE; DUAL SPECIFIC TYROSINE REGULATED KINASE 1A; N METHYL DEXTRO ASPARTIC ACID; PROTEIN KINASE; PROTEIN S100B; PURKINJE CELL PROTEIN 4; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ETS 2; TRANSCRIPTION FACTOR SIM2; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; BRAIN SIZE; CELL IMMORTALIZATION; CHROMOSOME 21; CLINICAL FEATURE; DISEASE MODEL; DOWN SYNDROME; ENZYME ACTIVITY; GENE EXPRESSION PROFILING; GENE LIBRARY; GENE MUTATION; GENE OVEREXPRESSION; GENE TRANSLOCATION; GENOME ANALYSIS; HUMAN; IN VIVO STUDY; LEARNING; MEMORY; MICROARRAY ANALYSIS; MOUSE; MOUSE STRAIN; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; TRISOMY;

EID: 84860324061     PISSN: 00796123     EISSN: 18757855     Source Type: Book Series    
DOI: 10.1016/B978-0-444-54299-1.00009-1     Document Type: Chapter

References (215)

1. Adams D.J., Biggs P.J., Cox T., Davies R., van der Weyden L., Jonkers J., et al. Mutagenic insertion and chromosome engineering resource (MICER). Nature Genetics 2004, 36:867-871.
2. Ahn K.J., Jeong H.K., Choi H.S., Ryoo S.R., Kim Y.J., Goo J.S., et al. DYRKIA BAC transgenic mice show altered synaptic plasticity with learning and memory defects. Neurobiology of Disease 2006, 22:463-472.
3. Aldridge K., Reeves R.H., Olson L.E., Richtsmeier J.T. Differential effects of trisomy on brain shape and volume in related aneuploid mouse models. American Journal of Medical Genetics. Part A 2007, 143A:1060-1070.
4. Altafaj X., Dierssen M., Baamonde C., Marti E., Visa J., Guimera J., et al. Neurodevelopmental delay, motor abnormalities and cognitive deficits in transgenic mice overexpressing Dyrk1A (minibrain), a murine model of Down's syndrome. Human Molecular Genetics 2001, 10:1915-1923.
5. Altafaj X., Ortiz-Abalia J., Fernandez M., Potier M.C., Laffaire J., Andreu N., et al. Increased NR2A expression and prolonged decay of NMDA-induced calcium transient in cerebellum of TgDyrk1A mice, a mouse model of Down syndrome. Neurobiology of Disease 2008, 32:377-384.
6. Anneren G., Gebremedhin M. Trace-elements and transport proteins in serum of children with Down-syndrome and of healthy siblings living in the same environment. Human Nutrition-Clinical Nutrition 1987, 41C:291-299.
7. Arriagada C., Astorga C., Atwater I., Rojas E., Mears D., Caviedes R., et al. Endosomal abnormalities related to amyloid precursor protein in cholesterol treated cerebral cortex neuronal cells derived from trisomy 16 mice, an animal model of Down syndrome. Neuroscience Letters 2007, 423:172-177.
8. Arron J.R., Winslow M.M., Polleri A., Chang C.P., Wu H., Gao X., et al. NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21. Nature 2006, 441:595-600.
9. Avraham K.B., Schickler M., Sapoznikov D., Yarom R., Groner Y. Downs-syndrome-Abnormal neuromuscular-junction in tongue of transgenic mice with elevated levels of human CU/ZN-superoxide dismutase. Cell 1988, 54:823-829.
10. Avraham K.B., Sugarman H., Rotshenker S., Groner Y. Downs-syndrome-Morphological remodeling and increased complexity in the neuromuscular-junction of transgenic CuZn-superoxide dismutase mice. Journal of Neurocytology 1991, 20:208-215.
11. Azmitia E.C., Dolan K., Whitakerazmitia P.M. S-100B but not NGF, EGF, insulin or calmodulin is a CNS serotonergic growth-factor. Brain Research 1990, 516:354-356.
12. Baek K.H., Zaslavsky A., Lynch R.C., Britt C., Okada Y., Siarey R.J., et al. Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1. Nature 2009, 459:1126-1130. U1113.
13. Baxter L.L., Moran T.H., Richtsmeier J.T., Troncoso J., Reeves R.H. Discovery and genetic localization of Down syndrome cerebellar phenotypes using the Ts65Dn mouse. Human Molecular Genetics 2000, 9:195-202.
14. Belichenko N.P., Belichenko P.V., Kleschevnikov A.M., Salehi A., Reeves R.H., Mobley W.C. The "Down syndrome critical region" is sufficient in the mouse model to confer behavioral, neurophysiological, and synaptic phenotypes characteristic of Down syndrome. The Journal of Neuroscience 2009, 29:5938-5948.
15. Belichenko P.V., Kleschevnikov A.M., Salehi A., Epstein C.J., Mobley W.C. Synaptic and cognitive abnormalities in mouse models of Down syndrome: Exploring genotype-phenotype relationships. The Journal of Comparative Neurology 2007, 504:329-345.
16. Belichenko P.V., Klescrevnikov A.M., Masliah E., Wu C.B., Takimoto-Kimura R., Salehi A., et al. Excitatory-inhibitory relationship in the fascia dentata in the Ts65Dn mouse model of Down syndrome. The Journal of Comparative Neurology 2009, 512:453-466.
17. Belichenko P.V., Masliah E., Kleschevnikov A.M., Villar A.J., Epstein C.J., Salehi A., et al. Synaptic structural abnormalities in the Ts65Dn mouse model of Down syndrome. The Journal of Comparative Neurology 2004, 480:281-298.
18. Besson V., Brault V., Duchon A., Togbe D., Bizot J.-C., Quesniaux V.F.J., et al. Modeling the monosomy for the telomeric part of human chromosome 21 reveals haploinsufficient genes modulating the inflammatory and airway responses. Human Molecular Genetics 2007, 16:2040-2052.
19. Bianchi P., Ciani E., Guidi S., Trazzi S., Felice D., Grossi G., et al. Early pharmacotherapy restores neurogenesis and cognitive performance in the Ts65Dn mouse model for Down syndrome. The Journal of Neuroscience 2010, 30:8769-8779.
20. Bimonte-Nelson H.A., Hunter C.L., Nelson M.E., Granholm A.C.E. Frontal cortex BDNF levels correlate with working memory in an animal model of Down syndrome. Behavioural Brain Research 2003, 139:47-57.
21. Blazek J.D., Billingsley C.N., Newbauer A., Roper R.J. Embryonic and not maternal trisomy causes developmental attenuation in the Ts65Dn mouse model for Down syndrome. Developmental Dynamics 2010, 239:1645-1653.
22. Branchi I., Bichler Z., Minghetti L., Delabar J.M., Malchiodi-Albedi F., Gonzalez M.C., et al. Transgenic mouse in vivo library of human Down syndrome critical region 1: Association between DYRK1A overexpression, brain development abnormalities, and cell cycle protein alteration. Journal of Neuropathology and Experimental Neurology 2004, 63:429-440.
23. Braudeau J., Delatour B., Duchon A., Lopes-Pereira P., Dauphinot L., de Chaumont F., et al. Specific targeting of the GABA-A receptor {alpha}5 subtype by a selective inverse agonist restores cognitive deficits in Down syndrome mice. Journal of Psychopharmacology 2011, 25(8):1030-1042.
24. Brault V., Besson V., Magnol L., Duchon A., Hérault Y. Cre/loxP-mediated chromosome engineering of the mouse genome. Handbook of Experimental Pharmacology 2007, 189:1487-1495.
25. Brault V., Pereira P., Duchon A., Hérault Y. Modeling chromosomes in mouse to explore the function of genes, genomic disorders, and chromosomal organization. PLoS Genetics 2006, 2:e86.
26. Benavides-Piccione R., Dierssen M., Ballesteros-Yanez I., Martinez de Lagran M., Arbones M.L., Fotaki V., et al. Alterations in the phenotype of neocortical pyramidal cells in the Dyrk1A+/- mouse. Neurobiology of Disease 2005, 20:115-122.
27. Busciglio J., Pelsman A., Helguera P., Ashur-Fabian O., Pinhasov A., Brenneman D.E., et al. NAP and ADNF-9 protect normal and Down's syndrome cortical neurons from oxidative damage and apoptosis. Current Pharmaceutical Design 2007, 13:1091-1098.
28. Cardenas A.M., Allen D.D., Arriagada C., Olivares A., Bennett L.B., Caviedes R., et al. Establishment and characterization of immortalized neuronal cell lines derived from the spinal cord of normal and trisomy 16 fetal mice, an animal model of Down syndrome. Journal of Neuroscience Research 2002, 68:46-58.
29. Cardenas A.M., Arriagada C., Allen D.D., Caviedes R., Cortes J.F., Martin J., et al. Cell lines derived from hippocampal neurons of the normal and trisomy 16 mouse fetus (a model for Down syndrome) exhibit neuronal markers, cholinergic function, and functional neurotransmitter receptors. Experimental Neurology 2002, 177:159-170.
30. Cardenas A.M., Rodriguez M.P., Cortes M.P., Alvarez R.M., Wei W.Z., Rapoport S.I., et al. Calcium signals in cell lines derived from the cerebral cortex of normal and trisomy 16 mice. Neuroreport 1999, 10:363-369.
31. Cataldo A.M., Petanceska S., Peterhoff C.M., Terio N.B., Epstein C.J., Villar A., et al. App gene dosage modulates endosomal abnormalities of Alzheimer's disease in a segmental trisomy 16 mouse model of Down syndrome. The Journal of Neuroscience 2003, 23:6788-6792.
32. Caviedes P., Caviedes R., Rapoport S.I. Altered calcium currents in cultured sensory neurons of normal and trisomy 16 mouse fetuses, an animal model for human trisomy 21 (Down Syndrome). Biological Research 2006, 39:471-481.
33. Chabert C., Jamon M., Cherfouh A., Duquenne V., Smith D.J., Rubin E., et al. Functional analysis of genes implicated in Down syndrome: 1. Cognitive abilities in mice transpolygenic for Down syndrome chromosomal region-1 (DCR-1). Behavior Genetics 2004, 34:559-569.
34. Chakrabarti L., Best T.K., Cramer N.P., Carney R.S.E., Isaac J.T.R., Galdzicki Z., et al. Olig1 and Olig2 triplication causes developmental brain defects in Down syndrome. Nature Neuroscience 2010, 13:927-934. U939.
35. Chakrabarti L., Galdzicki Z., Haydar T.F. Defects in embryonic neurogenesis and initial synapse formation in the forebrain of the Ts65Dn mouse model of Down syndrome. The Journal of Neuroscience 2007, 27:11483-11495.
36. Chang Q., Gold P.E. Age-related changes in memory and in acetylcholine functions in the hippocampus in the Ts65Dn mouse, a model of Down syndrome. Neurobiology of Learning and Memory 2008, 89:167-177.
37. Chang K.T., Min K.T. Drosophila melanogaster homolog of Down syndrome critical region 1 is critical for mitochondrial function. Nature Neuroscience 2005, 8:1577-1585.
38. Chrast R., Scott H.S., Madani R., Huber L., Wolfer D.P., Prinz M., et al. Mice trisomic for a bacterial artificial chromosome with the single-minded 2 gene (Sim2) show phenotypes similar to some of those present in the partial trisomy 16 mouse models of Down syndrome. Human Molecular Genetics 2000, 9:1853-1864.
39. Clark S., Schwalbe J., Stasko M.R., Yarowsky P.J., Costa A.C.S. Fluoxetine rescues deficient neurogenesis in hippocampus of the Ts65Dn mouse model for Down syndrome. Experimental Neurology 2006, 200:256-261.
40. Contestabile A., Fila T., Ceccarelli C., Bonasoni P., Bonapace L., Santini D., et al. Cell cycle alteration and decreased cell proliferation in the hippocampal dentate gyrus and in the neocortical germinal matrix of fetuses with Down syndrome and in Ts65Dn mice. Hippocampus 2007, 17:665-678.
41. Costa A.C.S., Grybko M.J. Deficits in hippocampal CA1 LTP induced by TBS but not HFS in the Ts65Dn mouse: A model of Down syndrome. Neuroscience Letters 2005, 382:317-322.
42. Costa A.C.S., Scott-McKean J.J., Stasko M.R. Acute injections of the NMDA receptor antagonist memantine rescue performance deficits of the Ts65Dn mouse model of Down syndrome on a fear conditioning test. Neuropsychopharmacology 2008, 33:1624-1632.
43. Coussons-Read M.E., Crnic L.S. Behavioral assessment of the Ts65Dn mouse, a model for Down syndrome: Altered behavior in the elevated plus maze and open field. Behavior Genetics 1996, 26:7-13.
44. Dauphinot L., Lyle R., Rivals I., Dang M.T., Moldrich R.X., Golfier G., et al. The cerebellar transcriptome during postnatal development of the Ts1Cje mouse, a segmental trisomy model for Down syndrome. Human Molecular Genetics 2005, 14:373-384.
45. Davisson M.T., Schmidt C., Akeson E.C. Segmental trisomy of murine chromosome 16: A new model system for studying Down syndrome. Progress in Clinical and Biological Research 1990, 360:263-280.
46. Davisson M.T., Schmidt C., Reeves R.H., Irving N.G., Akeson E.C., Harris B.S., et al. Segmental trisomy as a mouse model for Down syndrome. Progress in Clinical and Biological Research 1993, 384:117-133.
47. Deitz S.L., Roper R.J. Trisomic and allelic differences influence phenotypic variability during development of Down syndrome mice. Genetics 2011, 189(4):1487-1495.
48. Demas G.E., Nelson R.J., Krueger B.K., Yarowsky O.J. Spatial memory deficits in segmental trisomic Ts65Dn mice. Behavioural Brain Research 1996, 82:85-92.
49. Demas G.E., Nelson R.J., Krueger B.K., Yarowsky P.J. Impaired spatial working and reference memory in segmental trisomy (Ts65Dn) mice. Behavioural Brain Research 1998, 90:199-201.
50. Dierssen M., Arque G., McDonald J., Andreu N., Martinez-Cue C., Florez J., et al. Behavioral characterization of a mouse model overexpressing DSCR1/RCAN1. PLoS One 2011, 6(2):e17010.
51. Dierssen M., Benavides-Piccione R., Martinez-Cue C., Estivill X., Florez J., Elston G.N., et al. Alterations of neocortical pyramidal cell phenotype in the Ts65Dn mouse model of Down syndrome: Effects of environmental enrichment. Cerebral Cortex 2003, 13:758-764.
52. Dierssen M., Herault Y., Estivill X. Aneuploidy: From a physiological mechanism of variance to Down syndrome. Physiological Reviews 2009, 89:887-920.
53. Donato R., Sorci G., Riuzzi F., Arcuri C., Bianchi R., Brozzi F., et al. S100B's double life: Intracellular regulator and extracellular signal. Biochimica et Biophysica Acta 2009, 1793:1008-1022.
54. Dorsey S.G., Bambrick L.L., Balice-Gordon R.J., Krueger B.K. Failure of brain-derived neurotrophic factor-dependent neuron survival in mouse trisomy 16. The Journal of Neuroscience 2002, 22:2571-2578.
55. Dorsey S.G., Renn C.L., Carim-Todd L., Barrick C.A., Bambrick L., Krueger B.K., et al. In vivo restoration of physiological levels of truncated TrkB.T1 receptor rescues neuronal cell death in a trisomic mouse model. Neuron 2006, 51:21-28.
56. Duce J.A., Tsatsanis A., Cater M.A., James S.A., Robb E., Wikhe K., et al. Iron-export ferroxidase activity of beta-amyloid precursor protein is inhibited by zinc in Alzheimer's disease. Cell 2010, 142:857-867.
57. Duchon A., Pothion S., Brault V., Sharp A.J., Tybulewicz V.L.J., Fisher E.M.C., et al. The telomeric part of the human chromosome 21 from Cstb to Prmt2 is not necessary for the locomotor and short-term memory deficits observed in the Tc1 mouse model of Down syndrome. Behavioural Brain Research 2011, 217:271-281.
58. Duchon A., Raveau M., Chevalier C., Nalesso V., Sharp A.J., Herault Y. Identification of the translocation breakpoints in the Ts65Dn and Ts1Cje mouse lines: Relevance for modeling Down syndrome. Mammalian Genome 2011, 22(11-12):674-684.
59. Elson A., Bernstein Y., Degani H., Levanon D., Benhur H., Groner Y. Gene dosage and Downs-syndrome-Metabolic and enzymatic changes in PC12 cells overexpressing transfected human liver-type phosphofructokinase. Somatic Cell and Molecular Genetics 1992, 18:143-161.
60. Elson A., Levanon D., Weiss Y., Groner Y. Overexpression of Liver-type phosphofructokinase (PFKL) in transgenic-PFKL Mice-Implication for gene dosage in Trisomy-21. The Biochemical Journal 1994, 299:409-415.
61. Ema M., Ikegami S., Hosoya T., Mimura J., Ohtani H., Nakao K., et al. Mild impairment of learning and memory in mice overexpressing the mSim2 gene located on chromosome 16: An animal model of Down's syndrome. Human Molecular Genetics 1999, 8:1409-1415.
62. Epstein C.J., Avraham K.B., Lovett M., Smith S., Elroystein O., Rotman G., et al. Transgenic mice with increased Cu/Zn-superoxide dismutase activity-Animal-model of dosage effects in Down-syndrome. Proceedings of the National Academy of Sciences of the United States of America 1987, 84:8044-8048.
63. Ermak G., Cheadle C., Becker K.G., Harris C.D., Davies K.J.A. DSCR1 (Adapt78) modulates expression of SOD1. The FASEB Journal 2004, 18:62-69.
64. Ermak G., Harris C.D., Davies K.J.A. The DSCR1 (Adapt78) isoform 1 protein calcipressin 1 inhibits calcineurin and protects against acute calcium-mediated stress damage, including transient oxidative stress. The FASEB Journal 2002, 16(8):814-824.
65. Escorihuela R.M., Vallina I.F., Martínez-Cué C., Baamonde C., Dierssen M., Tobeña A., et al. Impaired short- and long-term memory in Ts65Dn mice, a model for Down syndrome. Neuroscience Letters 1998, 247:171-174.
66. Faizi M., Bader P.L., Tun C., Encarnacion A., Kleschevnikov A., Belichenko P., et al. Comprehensive behavioral phenotyping of Ts65Dn mouse model of Down syndrome: Activation of pradrenergic receptor by xamoterol as a potential cognitive enhancer. Neurobiology of Disease 2011, 43:397-413.
67. Fernandez F., Garner C.C. Object recognition memory is conserved in Ts1Cje, a mouse model of Down syndrome. Neuroscience Letters 2007, 421:137-141.
68. Fernandez F., Garner C.C. Episodic-like memory in Ts65Dn, a mouse model of Down syndrome. Behavioural Brain Research 2008, 188:233-237.
69. Fernandez F., Morishita W., Zuniga E., Nguyen J., Blank M., Malenka R.C., et al. Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome. Nature Neuroscience 2007, 10:411-413.
70. Fotaki V., Dierssen M., Alcantara S., Martinez S., Marti E., Casas C., et al. Dyrk1A haploinsufficiency affects viability and causes developmental delay and abnormal brain morphology in mice. Molecular Cell Biology 2002, 22:6636-6647.
71. Fournier R.E.K., Ruddle F.H. Microcell-mediated transfer of murine chromosomes into mouse, Chinese-hamster, and human somatic-cells. Proceedings of the National Academy of Sciences of the United States of America 1977, 74:319-323.
72. Frederikse P.H., Ren X.O. Lens defects and age-related fiber cell degeneration in a mouse model of increased APPP gene dosage in Down syndrome. The American Journal of Pathology 2002, 161:1985-1990.
73. Friend W.C., Clapoff S., Landry C., Becker L.E., Ohanlon D., Allore R.J., et al. Cell-specific expression of high-levels of human S100-beta in transgenic mouse-brain is dependent on gene dosage. The Journal of Neuroscience 1992, 12:4337-4346.
74. Fuentes J.J., Genesca L., Kingsbury T.J., Cunningham K.W., Perez-Riba M., Estivill X., et al. DSCR1, overexpressed in Down syndrome, is an inhibitor of calcineurin-mediated signaling pathways. Human Molecular Genetics 2000, 9:1681-1690.
75. Fuentes J.J., Pritchard M.A., Planas A.M., Bosch A., Ferrer I., Estivill X. A new human gene from the Down-syndrome critical region encodes a proline-rich protein highly expressed in fetal brain and heart. Human Molecular Genetics 1995, 4:1935-1944.
76. Galante M., Jani H., Vanes L., Daniel H., Fisher E.M.C., Tybulewicz V.L.J., et al. Impairments in motor coordination without major changes in cerebellar plasticity in the Tc1 mouse model of Down syndrome. Human Molecular Genetics 2009, 18:1449-1463.
77. Games D., Adams D., Alessandrini R., Barbour R., Berthelette P., Blackwell C., et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 1995, 373:523-527.
78. Gardiner K., Fortna A., Bechtel L., Davisson M.T. Mouse models of Down syndrome: How useful can they be? Comparison of the gene content of human chromosome 21 with orthologous mouse genomic regions. Gene 2003, 318:137-147.
79. Gerlai R., Roder J. Female-specific hyperactivity in S100-beta transgenic mice does not habituate in open-field. Behavioural Brain Research 1993, 59:119-124.
80. Gerlai R., Roder J. Spatial and nonspatial learning in mice: Effects of S100 beta overexpression and age. Neurobiology of Learning and Memory 1996, 66:143-154.
81. Granholm A.C., Sanders L.A., Crnic L.S. Loss of cholinergic phenotype in basal forebrain coincides with cognitive decline in a mouse model of Down's syndrome. Experimental Neurology 2000, 161:647-663.
82. Groner Y., Elroystein O., Avraham K.B., Yarom R., Schickler M., Knobler H., et al. Down syndrome clinical symptoms are manifested in transfected cells and transgenic mice overexpressing the human Cu/Zn-superoxide dismutase gene. Journal de Physiologie 1990, 84:53-77.
83. Gropp A., Kolbus U., Giers D. Systematic approach to study of trisomy in mouse. 2. Cytogenetics and Cell Genetics 1975, 14:42-62.
84. Guedj F., Sebrie C., Rivals I., Ledru A., Paly E., Bizot J.C., et al. Green tea polyphenols rescue of brain defects induced by overexpression of DYRK1A. PLoS One 2009, 4(2):e4606.
85. Guimera J., Casas C., Pucharcos C., Solans A., Domenech A., Planas A.M., et al. A human homologue of Drosophila minibrain (MNB) is expressed in the neuronal regions affected in Down syndrome and maps to the critical region. Human Molecular Genetics 1996, 5:1305-1310.
86. Gurney M.E., Pu H.F., Chiu A.Y., Dalcanto M.C., Polchow C.Y., Alexander D.D., et al. Motor-neuron degeneration in mice that express a human Cu, Zn superoxide-dismutase mutation. Science 1994, 264:1772-1775.
87. Hammerle B., Carnicero A., Elizalde C., Ceron J., Martinez S., Tejedor F.J. Expression patterns and subcellular localization of the Down syndrome candidate protein MNB/DYRK1A suggest a role in late neuronal differentiation. The European Journal of Neuroscience 2003, 17:2277-2286.
88. Harris-Cerruti C., Kamsler A., Kaplan B., Lamb B., Segal M., Groner Y. Functional and morphological alterations in compound transgenic mice overexpressing Cu/Zn superoxide dismutase and amyloid precursor protein. The European Journal of Neuroscience 2004, 19:1174-1190. 2913.
89. Haydar T.F., Blue M.E., Molliver M.E., Krueger B.K., Yarowsky P.J. Consequences of trisomy 16 for mouse brain development: Corticogenesis in a model of Down syndrome. The Journal of Neuroscience 1996, 16:6175-6182.
90. Haydar T.F., Nowakowski R.S., Yarowsky P.J., Krueger B.K. Role of founder cell deficit and delayed neuronogenesis in microencephaly of the trisomy 16 mouse. The Journal of Neuroscience 2000, 20:4156-4164.
91. Herault Y., Rassoulzadegan M., Cuzin F., Duboule D. Engineering chromosomes in mice through targeted meiotic recombination (TAMERE). Nature Genetics 1998, 20:381-384.
92. Hewitt C.A., Ling K.H., Merson T.D., Simpson K.M., Ritchie M.E., King S.L., et al. Gene network disruptions and neurogenesis defects in the adult Ts1Cje mouse model of Down syndrome. PLoS One 2010, 5(7):e11561.
93. Higgins L.S., Catalano R., Quon D., Cordell B. Transgenic mice expressing human beta-APP751, but not Mice expressing beta-APP695, display early Alzheimers disease-like histopathology. Alzheimers disease: Amyloid precusor proteins, signal transduction, and neuronal transplantation. 1993, 224-227. Annals of the New York Academy of Sciences. R.M. Nitsch, J.H. Growdon, S. Corkin, R.J. Wurtman (Eds.).
94. Hill C.A., Reeves R.H., Richtsmeier J.T. Effects of aneuploidy on skull growth in a mouse model of Down syndrome. Journal of Anatomy 2007, 210:394-405.
95. Hoeffer C.A., Dey A., Sachan N., Wong H., Patterson R.J., Shelton J.M., et al. The Down syndrome critical region protein RCAN1 regulates long-term potentiation and memory via inhibition of phosphatase signaling. The Journal of Neuroscience 2007, 27:13161-13172.
96. Holtzman D.M., Li Y.W., Dearmond S.J., McKinley M.P., Gage F.H., Epstein C.J., et al. Mouse model of neurodegeneration-Atrophy of basal forebrain cholinergic neurons in trisomy-16 transplants. Proceedings of the National Academy of Sciences of the United States of America 1992, 89:1383-1387.
97. Holtzman D.M., Santucci D., Kilbridge J., ChuaCouzens J., Fontana D.J., Daniels S.E., et al. Developmental abnormalities and age-related neurodegeneration in a mouse model of Down syndrome. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:13333-13338.
98. Hsiao K.K., Borchelt D.R., Olson K., Johannsdottir R., Kitt C., Yunis W., et al. Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins. Neuron 1995, 15:1203-1218.
99. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., et al. Correlative memory deficits, A beta elevation, and amyloid plaques in transgenic mice. Science 1996, 274:99-102.
100. Hyde L.A., Frisone D.F., Crnic L.S. Ts65Dn mice, a model for Down syndrome, have deficits in context discrimination learning suggesting impaired hippocampal function. Behavioural Brain Research 2001, 118:53-60.
101. Incerti M., Toso L., Vink J., Roberson R., Nold C., Abebe D., et al. Prevention of learning deficit in a Down syndrome model. Obstetrics and Gynecology 2011, 117:354-361.
102. Insausti A.M., Megías M., Crespo D., Cruz-Orive L.M., Dierssen M., Vallina I.F., et al. Hippocampal volume and neuronal number in Ts65Dn mice: A murine model of Down syndrome. Neuroscience Letters 1998, 253:175-178.
103. Ishihara K., Amano K., Takaki E., Ebrahim A.S., Shimohata A., Shibazaki N., et al. Increased lipid peroxidation in Down's syndrome mouse models. Journal of Neurochemistry 2009, 110:1965-1976.
104. Ishihara K., Amano K., Takaki E., Shimohata A., Sago H., Epstein C.J., et al. Enlarged brain ventricles and impaired neurogenesis in the Ts1Cje and Ts2Cje mouse models of Down syndrome. Cerebral Cortex 2010, 20:1131-1143.
105. Iwamoto K., Bundo M., Yamamoto M., Ozawa H., Saito T., Kato T. Decreased expression of NEFH and PCP4/PEP19 in the prefrontal cortex of alcoholics. Neuroscience Research 2004, 49:379-385.
106. Keating D.J., Dubach D., Zanin M.P., Yu Y., Martin K., Zhao Y.F., et al. DSCR1/RCAN1 regulates vesicle exocytosis and fusion pore kinetics: Implications for Down syndrome and Alzheimer's disease. Human Molecular Genetics 2008, 17:1020-1030.
107. Kleschevnikov A.M., Belichenko P.V., Epstein C.J., Villar A.J., Malenka R., Mobley W.C. Reduced LTP and enhanced inhibition in dentate gyrus of Ts65Dn mice, a model for Down's syndrome. Neurobiology of Aging 2004, 25:S252. S252.
108. Kleschevnikov A.M., Belichenko P.V., Villar A.J., Epstein C.J., Malenka R.C., Mobley W.C. Hippocampal long-term potentiation suppressed by increased inhibition in the Ts65Dn mouse, a genetic model of Down syndrome. The Journal of Neuroscience 2004, 24:8153-8160.
109. Knobler H., Weiss Y., Peled M., Groner Y. Impaired glucose-induced insulin response in transgenic mice overexpressing the L-phosphofructokinase gene. Diabetes 1997, 46:1414-1418.
110. Kuo Y.M., Kokjohn T.A., Beach T.G., Sue L.I., Brune D., Lopez J.C., et al. Comparative analysis of amyloid-beta chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer's disease brains. The Journal of Biological Chemistry 2001, 276:12991-12998.
111. Kurt M.A., Davies D.C., Kidd M., Dierssen M., Florez J. Synaptic deficit in the temporal cortex of partial trisomy 16 (Ts65Dn) mice. Brain Research 2000, 858:191-197.
112. Kurt M.A., Kafa M.I., Dierssen M., Davies D.C. Deficits of neuronal density in CA1 and synaptic density in the dentate gyrus, CA3 and CA1, in a mouse model of Down syndrome. Brain Research 2004, 1022:101-109.
113. Lamb B.T., Sisodia S.S., Lawler A.M., Slunt H.H., Kitt C.A., Kearns W.G., et al. Introduction and expression of the 400 kilobase precursor amyloid protein gene in transgenic mice. Nature Genetics 1993, 5:22-29.
114. Le Pecheur M., Bourdon E., Paly E., Farout L., Friguet B., London J. Oxidized SOD1 alters proteasome activities in vitro and in the cortex of SOD1 overexpressing mice. FEBS Letters 2005, 579:3613-3618.
115. Levin E.D., Christopher N.C., Lateef S., Elamir B.M., Patel M., Liang L.P., et al. Extracellular superoxide dismutase overexpression protects against aging-induced cognitive impairment in mice. Behavior Genetics 2002, 32:119-125.
116. Li Z., Yu T., Morishima M., Pao A., LaDuca J., Conroy J., et al. Duplication of the entire 22.9 Mb human chromosome 21 syntenic region on mouse chromosome 16 causes cardiovascular and gastrointestinal abnormalities. Human Molecular Genetics 2007, 16:1359-1366.
117. Liu F., Liang Z.H., Wegiel J., Hwang Y.W., Iqbal K., Grundke-Iqbal I., et al. Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome. The FASEB Journal 2008, 22:3224-3233.
118. Liu C., Morishima M., Yu T., Matsui S., Zhang L., Fu D., et al. Genetic analysis of Down syndrome-associated heart defects in mice. Human Genetics 2011, 130:623-632.
119. Lopes Pereira P., Magnol L., Sahun I., Brault V., Duchon A., Prandini P., et al. A new mouse model for the trisomy of the Abcg1-U2af1 region reveals the complexity of the combinatorial genetic code of Down syndrome. Human Molecular Genetics 2009, 18:4756-4769.
120. Lorenzi H.A., Reeves R.H. Hippocampal hypocellularity in the Ts65Dn mouse originates early in development. Brain Research 2006, 1104:153-159.
121. Mariggio M.A., Fulle S., Calissano P., Nicoletti I., Fano G. The brain protein S-100ab induces apoptosis in PC12 cells. Neuroscience 1994, 60:29-35.
122. Marshak D.R., Pesce S.A., Stanley L.C., Griffin W.S.T. Increased S100-beta neurotrophic activity in Alzheimers-disease temporal-lobe. Neurobiology of Aging 1992, 13:1-7.
123. Martinez-Cue C., Baamonde C., Lumbreras M., Paz J., Davisson M.T., Schmidt C., et al. Differential effects of environmental enrichment on behavior and learning of male and female Ts65Dn mice, a model for Down syndrome. Behavioural Brain Research 2002, 134:185-200.
124. Martinez-Cue C., Baamonde C., Lumbreras M.A., Vallina I.F., Dierssen M., Florez J. A murine model for Down syndrome shows reduced responsiveness to pain. Neuroreport 1999, 10:1119-1122.
125. Martinez-Cue C., Rueda N., Garcia E., Davisson M.T., Schmidt C., Florez J. Behavioral, cognitive and biochemical responses to different environmental conditions in male Ts65Dn mice, a model of Down syndrome. Behavioural Brain Research 2005, 163:174-185.
126. Moechars D., Gilis M., Kuiperi C., Laenen I., Van Leuven F. Aggressive behaviour in transgenic mice expressing APP is alleviated by serotonergic drugs. Neuroreport 1998, 9:3561-3564.
127. Moechars D., Lorent K., DeStrooper B., Dewachter I., VanLeuven F. Expression in brain of amyloid precursor protein mutated in the alpha-secretase site causes disturbed behavior, neuronal degeneration and premature death in transgenic mice. The EMBO Journal 1996, 15:1265-1274.
128. Moldrich R.X., Dauphinot L., Laffaire J., Rossier J., Potier M.-C. Down syndrome gene dosage imbalance on cerebellum development. Progress in Neurobiology 2007, 82:87-94.
129. Moldrich R.X., Dauphinot L., Laffaire J., Vitalis T., Herault Y., Beart P.M., et al. Proliferation deficits and gene expression dysregulation in Down's syndrome (Ts1Cje) neural progenitor cells cultured from neurospheres. Journal of Neuroscience Research 2009, 87:3143-3152.
130. Moon J., Chen M., Gandhy S.U., Strawderman M., Levitsky D.A., Maclean K.N., et al. Perinatal choline supplementation improves cognitive functioning and emotion regulation in the Ts65Dn mouse model of Down syndrome. Behavioral Neuroscience 2010, 124:346-361.
131. Moore C.S. Postnatal lethality and cardiac anomalies in the Ts65Dn Down syndrome mouse model. Mammalian Genome 2006, 17:1005-1012.
132. Moran P.M., Higgins L.S., Cordell B., Moser P.C. Age-related learning-deficits in transgenic mice expressing the 751-amino acid isoform of human beta-amyloid precursor protein. Proceedings of the National Academy of Sciences of the United States of America 1995, 92:5341-5345.
133. Morice E., Andreae L.C., Cooke S.F., Vanes L., Fisher E.M.C., Tybulewicz V.L.J., et al. Preservation of long-term memory and synaptic plasticity despite short-term impairments in the Tc1 mouse model of Down syndrome. Learning & Memory 2008, 15:492-500.
134. Mouton-Liger F., Thomas S., Rattenbach R., Magnol L., Larigaldie V., Ledru A., et al. PCP4 (PEP19) overexpression induces premature neuronal differentiation associated with Ca(2+)/calmodulin-dependent kinase II delta activation in mouse models of Down syndrome. The Journal of Comparative Neurology 2011, 519(14):2779-2802.
135. Muller C.M., Akhavan A.C., Bette M. Possible role of S-100 in glia neuronal signaling involved in activity-dependent plasticity in the developing mammalian cortex. Journal of Chemical Neuroanatomy 1993, 6:215-227.
136. Nagase T., Ishikawa K., Kikuno R., Hirosawa M., Nomura N., Ohara O. Prediction of the coding sequences of unidentified human genes. XV. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro. DNA Research 1999, 6:337-345.
137. Nambu J.R., Franks R.G., Hu S., Crews S.T. The single-minded gene of drosophila is required for the expression of genes important for the development of CNS midline cells. Cell 1990, 63:63-75.
138. Nambu J.R., Lewis J.O., Wharton K.A., Crews S.T. The drosophila single-minded gene encodes a helix-loop-helix protein that acts as a master regulator of CNS midline development. Cell 1991, 67:1157-1167.
139. Netzer W.J., Powell C., Nong Y., Blundell J., Wong L., Duff K., et al. Lowering beta-amyloid levels rescues learning and memory in a Down syndrome mouse model. PLoS One 2010, 5:e10943.
140. Nishiyama H., Knopfel T., Endo S., Itohara S. Glial protein S100B modulates long-term neuronal synaptic plasticity. Proceedings of the National Academy of Sciences of the United States of America 2002, 99:4037-4042.
141. O'Doherty A., Ruf S., Mulligan C., Hildreth V., Errington M.L., Cooke S., et al. An aneuploid mouse strain carrying human chromosome 21 with Down syndrome phenotypes. Science 2005, 309:2033-2037.
142. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: Intracellular a beta and synaptic dysfunction. Neuron 2003, 39:409-421.
143. Olson L.E., Richtsmeier J.T., Leszl J., Reeves R.H. A chromosome 21 critical region does not cause specific Down syndrome phenotypes. Science 2004, 306:687-690.
144. Olson L.E., Roper R.J., Baxter L.L., Carlson E.J., Epstein C.J., Reeves R.H. Down syndrome mouse models Ts65Dn, Ts1Cje, and Ms1Cje/Ts65Dn exhibit variable severity of cerebellar phenotypes. Developmental Dynamics 2004, 230:581-589.
145. Olson L.E., Roper R.J., Sengstaken C.L., Peterson E.A., Aquino V., Galdzicki Z., et al. Trisomy for the Down syndrome 'critical region' is necessary but not sufficient for brain phenotypes of trisomic mice. Human Molecular Genetics 2007, 16:774-782.
146. Oury T.D., Ho Y.S., Piantadosi C.A., Crapo J.D. Extracellular superoxide dismutase, nitric oxide, and central nervous system O2 toxicity. Proceedings of the National Academy of Sciences of the United States of America 1992, 89:9715-9719.
147. Ortiz-Abalia J., Sahún I., Altafaj X., Andreu N., Estivill X., Dierssen M., et al. Targeting Dyrk1A with AAVshRNA attenuates motor alterations in TgDyrk1A, a mouse model of Down syndrome. American Journal of Human Genetics 2008, 83:479-488.
148. Peled-Kamar M., Degani H., Bendel P., Margalit R., Groner Y. Altered brain glucose metabolism in transgenic-PFKL mice with elevated L-phosphofructokinase: In vivo NMR studies. Brain Research 1998, 810:138-145.
149. Perez-Cremades D., Hernandez S., Blasco-Ibanez J.M., Crespo C., Nacher J., Varea E. Alteration of inhibitory circuits in the somatosensory cortex of Ts65Dn mice, a model for Down's syndrome. Journal of Neural Transmission 2010, 117:445-455.
150. Popov V.I., Kleschevnikov A.M., Klimenko O.A., Stewart M.G., Belichenko P.V. Three-dimensional synaptic ultrastructure in the dentate gyrus and hippocampal area CA3 in the Ts65Dn mouse model of Down syndrome. The Journal of Comparative Neurology 2011, 519:1338-1354.
151. Pratico D., Uryu K., Leight S., Trojanowswki J.Q., Lee V.M.Y. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. The Journal of Neuroscience 2001, 21:4183-4187.
152. Priller C., Bauer T., Mitteregger G., Krebs B., Kretzschmar H.A., Herms J. Synapse formation and function is modulated by the amyloid precursor protein. The Journal of Neuroscience 2006, 26:7212-7221.
153. Pruitt K.D., Tatusova T., Maglott D.R. NCBI reference sequence project: Update and current status. Nucleic Acids Research 2003, 31:34-37.
154. Quon D., Wang Y., Catalano R., Scardina J.M., Murakami K., Cordell B. Formation of beta-amyloid protein deposits in brains of transgenic mice. Nature 1991, 352:239-241.
155. Rachidi M., Lopes C., Costantine M., Delabar J.M. C21orf5, a new member of Dopey family involved in morphogenesis, could participate in neurological alterations and mental retardation in Down syndrome. DNA Research 2005, 12:203-210.
156. Rachidi M., Lopes C., VayssetteS C., Smith D.J., Rubin E.M., Delabar J.M. New cerebellar phenotypes in YAC transgenic mouse in vivo library of human Down syndrome critical region-1. Biochemical and Biophysical Research Communications 2007, 364:488-494.
157. Ramirez-Solis R., Liu P., Bradley A. Chromosome engineering in mice. Nature 1995, 378:720-724.
158. Reeves R.H., Irving N.G., Moran T.H., Wohn A., Kitt C., Sisodia S.S., et al. A mouse model for Down syndrome exhibits learning and behaviour deficits. Nature Genetics 1995, 11:177-184.
159. Reeves R.H., Yao J.B., Crowley M.R., Buck S., Zhang X.F., Yarowsky P., et al. Astrocytosis and axonal proliferation in the hippocampus of S100b transgenic mice. Proceedings of the National Academy of Sciences of the United States of America 1994, 91:5359-5363.
160. Reinholdt L.G., Ding Y., Gilbert G.T., Czechanskibr A., Solzak J.P., Roper R.J., et al. Molecular characterization of the translocation breakpoints in the Down syndrome mouse model Ts65Dn. Mammalian genome 2011, 22(11-12):685-691.
161. Reynolds L.E., Watson A.R., Baker M., Jones T.A., D'Amico G., Robinson S.D., et al. Tumour angiogenesis is reduced in the Tc1 mouse model of Down's syndrome. Nature 2010, 465:813-817.
162. Richardson J.A., Burns D.K. Mouse models of Alzheimer's disease: A quest for plaques and tangles. ILAR Journal 2002, 43:89-99.
163. Roper R.J., Baxter L.L., Saran N.G., Klinedinst D.K., Beachy P.A., Reeves R.H. Defective cerebellar response to mitogenic Hedgehog signaling in Down's syndrome mice. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:1452-1456.
164. Rothermundt M., Peters M., Prehn J.H.M., Arolt V. S100B in brain damage and neurodegeneration. Microscopy Research and Technique 2003, 60:614-632.
165. Rueda N., Florez J., Martinez-Cue C. Chronic pentylenetetrazole but not donepezil treatment rescues spatial cognition in Ts65Dn mice, a model for Down syndrome. Neuroscience Letters 2008, 433:22-27.
166. Rueda N., Llorens-Martin M., Florez J., Valdizan E., Banerjee P., Trejo J.L., et al. Memantine normalizes several phenotypic features in the Ts65Dn mouse model of Down syndrome. Journal of Alzheimer's Disease 2010, 21:277-290.
167. Ryoo S.R., Cho H.J., Lee H.W., Jeong H.K., Radnaabazar C., Kim Y.S., et al. Dual-specificity tyrosine(Y)-phosphorylation regulated kinase 1A-mediated phosphorylation of amyloid precursor protein: Evidence for a functional link between Down syndrome and Alzheimer's disease. Journal of Neurochemistry 2008, 104:1333-1344.
168. Ryoo S.R., Jeong H.K., Radnaabazar C., Yoo J.J., Cho H.J., Lee H.W., et al. DYRK1A-mediated hyperphosphorylation of Tau-A functional link between Down syndrome and Alzheimer disease. The Journal of Biological Chemistry 2007, 282:34850-34857.
169. Sago H., Carlson E.J., Smith D.J., Kilbridge J., Rubin E.M., Mobley W.C., et al. Ts1Cje, a partial trisomy 16 mouse model for Down syndrome, exhibits learning and behavioral abnormalities. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:6256-6261.
170. Sago H., Carlson E.J., Smith D.J., Rubin E.M., Crnic L.S., Huang T.T., et al. Genetic dissection of region associated with behavioral abnormalities in mouse models for Down syndrome. Pediatric Research 2000, 48:606-613.
171. Salehi A., Delcroix J.D., Belichenko P.V., Zhan K., Wu C., Valletta J.S., et al. Increased App expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration. Neuron 2006, 51:29-42.
172. Salehi A., Faizi M., Colas D., Valletta J., Laguna J., Takimoto-Kimura R., et al. Restoration of norepinephrine-modulated contextual memory in a mouse model of Down syndrome. Science Translational Medicine 2009, 1(7):7ra17.
173. Sebrie C., Chabert C., Ledru A., Guedj F., Po C., Smith D.J., et al. Increased dosage of DYRK1A and brain volumetric alterations in a YAC model of partial trisomy 21. The Anatomical Record: Advances in Integrative Anatomy and Evolutionary Biology 2008, 291:254-262.
174. Seo H., Isacson O. Abnormal APP, cholinergic and cognitive function in Ts65Dn Down's model mice. Experimental Neurology 2005, 193:469-480.
175. Shapiro L.A., Marks A., Whitaker-Azmitia P.M. Increased clusterin expression in old but not young adult S100B transgenic mice: Evidence of neuropathological aging in a model of Down Syndrome. Brain Research 2004, 1010:17-21.
176. Shapiro L.A., Whitaker-Azmitia P.M. Expression levels of cytoskeletal proteins indicate pathological aging of S100B transgenic mice: An immunohistochemical study of MAP-2, drebrin and GAP-43. Brain Research 2004, 1019:39-46.
177. Shinohara T., Tomizuka K., Miyabara S., Takehara S., Kazuki Y., Inoue J., et al. Mice containing a human chromosome 21 model behavioral impairment and cardiac anomalies of Down's syndrome. Human Molecular Genetics 2001, 10:1163-1175.
178. Shukkur E.A., Shimohata A., Akagi T., Yu W.X., Yamaguchi M., Murayama M., et al. Mitochondrial dysfunction and tau hyperphosphorylation in Ts1Cje, a mouse model for Down syndrome. Human Molecular Genetics 2006, 15:2752-2762.
179. Siarey R.J., Carlson E.J., Epstein C.J., Balbo A., Rapoport S.I., Galdzicki Z. Increased synaptic depression in the Ts65Dn mouse, a model for mental retardation in Down syndrome. Neuropharmacology 1999, 38:1917-1920.
180. Siarey R.J., Stoll J., Rapoport S.I., Galdzicki Z. Altered long-term potentiation in the young and old Ts65Dn mouse, a model for Down Syndrome. Neuropharmacology 1997, 36:1549-1554.
181. Siarey R.J., Villar A.J., Epstein C.J., Galdzicki Z. Abnormal synaptic plasticity in the Ts1Cje segmental trisomy 16 mouse model of Down syndrome. Neuropharmacology 2005, 49:122-128.
182. Skold K., Svensson M., Nilsson A., Zhang X.Q., Nydahl K., Caprioli R.M., et al. Decreased striatal levels of PEP-19 following MPTP lesion in the mouse. Journal of Proteome Research 2006, 5:262-269.
183. Slemmon J.R., Morgan J.I., Fullerton S.M., Danho W., Hilbush B.S., Wengenack T.M. Camstatins are peptide antagonists of calmodulin based upon a conserved structural motif in PEP-19, neurogranin, and neuromodulin. The Journal of Biological Chemistry 1996, 271:15911-15917.
184. Smith D.J., Rubin E.M. Functional screening and complex traits: Human 21q22.2 sequences affecting learning in mice. Human Molecular Genetics 1997, 6:1729-1733.
185. Smith D.J., Stevens M.E., Cheng J.F., Rubin E.M. Identification of genes affecting learning and memory in chromosome 21 YAC transgenic mice. Cytogenetics and Cell Genetics 1997, 79:49. 49.
186. Smith D.J., Stevens M.E., Sudanagunta S.P., Bronson R.T., Makhinson M., Watabe A.M., et al. Functional screening of 2 Mb of human chromosome 21q22.2 in transgenic mice implicates minibrain in learning defects associated with Down syndrome. Nature Genetics 1997, 16:28-36.
187. Smith D.J., Zhu Y.W., Zhang J.L., Cheng J.F., Rubin E.M. Construction of a panel of transgenic mice containing a contiguous 2-Mb set of YAC/P1 clones from human-chromosome 21q22.2. Genomics 1995, 27:425-434.
188. Song W.J., Sternberg L.R., KastenSportes C., VanKeuren M.L., Chung S.H., Slack A.C., et al. Isolation of human and murine homologues of the Drosophila minibrain gene: Human homologue maps to 21q22.2 in the Down syndrome "critical region" Genomics 1996, 38:331-339.
189. Stasko M.R., Costa A.C.S. Experimental parameters affecting the Morris water maze performance of a mouse model of Down syndrome. Behavioural Brain Research 2004, 154:1-17.
190. Stewart L.S., Persinger M.A., Cortez M.A., Snead O.C. Chronobiometry of behavioral activity in the Ts65Dn model of Down syndrome. Behavior Genetics 2007, 37:388-398.
191. Sumarsono S.H., Wilson T.J., Tymms M.J., Venter D.J., Corrick C.M., Kola R., et al. Down's syndrome-like skeletal abnormalities in Ets2 transgenic mice. Nature 1996, 379:534-537.
192. Sweeney J.E., Hohmann C.F., Ostergranite M.L., Coyle J.T. Neurogenesis of the basal forebrain in euploid and trisomy-16 mice-An animal-model for developmental disorders in Down syndrome. Neuroscience 1989, 31:413-425.
193. Tecott L.H. The genes and brains of mice and men. The American Journal of Psychiatry 2003, 160:646-656.
194. Tejedor F., Zhu X.R., Kaltenbach E., Ackermann A., Baumann A., Canal I., et al. Minibrain-A new-protein kinase family involved in postembryonic neurogenesis in drosophila. Neuron 1995, 14:287-301.
195. Trazzi S., Mitrugno V.M., Valli E., Fuchs C., Rizzi S., Guidi S., et al. APP-dependent up-regulation of Ptch1 underlies proliferation impairment of neural precursors in Down syndrome. Human Molecular Genetics 2011, 20:1560-1573.
196. Turner P.R., O'Connor K., Tate W.P., Abraham W.C. Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. Progress in Neurobiology 2003, 70:1-32.
197. Utal A.K., Stopka A.L., Roy M., Coleman P.D. PEP-19 immunohistochemistry defines the basal ganglia and associated structures in the adult human brain, and is dramatically reduced in Huntington's disease. Neuroscience 1998, 86:1055-1063.
198. Vacik T., Ort M., Gregorova S., Strnad P., Blatny R., Conte N., et al. Segmental trisomy of chromosome 17: A mouse model of human aneuploidy syndromes. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:4500-4505.
199. Vankeuren M., Drabkin H., Hart I., Harker D., Patterson D., Vora S. Regional assignment of human liver-type 6-phosphofructokinase to chromosome 21q22.3 by using somatic-cell hybrids and a monoclonal anti-l antibody. Human Genetics 1986, 74:34-40.
200. Venter J.C., Adams M.D., Myers E.W., Li P.W., Mural R.J., Sutton G.G., et al. The sequence of the human genome. Science 2001, 291:1304-1351.
201. Villar A.J., Belichenko P.V., Gillespie A.M., Kozy H.M., Mobley W.C., Epstein C.J. Identification and characterization of a new Down syndrome model, Ts Rb(12.17(16)) 2Cje, resulting from a spontaneous Robertsonian fusion between T(17(16))65Dn and mouse Chromosome 12. Mammalian Genome 2005, 16:79-90.
202. Vora S., Francke U. Assignment of the human-gene for liver-type 6-phosphofructokinase isoenzyme (PFKL) to chromosome 21 by using somatic-cell hybrids and monoclonal anti-L antibody. Proceedings of the National Academy of Sciences of the United States of America 1981, 78:3738-3742.
203. Wei P., Blundon J.A., Rong Y., Zakharenko S.S., Morgan J.I. Impaired locomotor learning and altered cerebellar synaptic plasticity in pep-19/PCP4-null mice. Molecular and Cellular Biology 2011, 31:2838-2844.
204. Wenger G.R., Schmidt C., Davisson M.T. Operant conditioning in the Ts65Dn mouse: Learning. Behavior Genetics 2004, 34:105-119.
205. Westmark C.J., Westmark P.R., Malter J.S. Alzheimer's disease and Down syndrome rodent models exhibit audiogenic seizures. Journal of Alzheimer's Disease 2010, 20:1009-1013.
206. Whitaker-Azmitia P.M., Wingate M., Borella A., Gerlai R., Roder J., Azmitia E.C. Transgenic mice overexpressing the neurotrophic factor S-100 beta show neuronal cytoskeletal and behavioral signs of altered aging processes: Implications for Alzheimer's disease and Down's syndrome. Brain Research 1997, 776:51-60.
207. Winocur G., Roder J., Lobaugh N. Learning and memory in S100-beta transgenic mice: An analysis of impaired and preserved function. Neurobiology of Learning and Memory 2001, 75:230-243.
208. Wolvetang E.J., Bradfield O.M., Hatzistavrou T., Crack P.J., Busciglio J., Kola I., et al. Overexpression of the chromosome 21 transcription factor Ets2 induces neuronal apoptosis. Neurobiology of Disease 2003, 14:349-356.
209. Yan W., Wilson C.C., Haring J.H. 5-HT1A receptors mediate the neurotrophic effect of serotonin on developing dentate granule cells. Brain Research. Developmental Brain Research 1997, 98:185-190.
210. Yarom R., Sapoznikov D., Havivi Y., Avraham K.B., Schickler M., Groner Y. Premature aging changes in neuromuscular-junctions of transgenic mice with an extra human cuznsod gene-A model for tongue pathology in Downs-syndrome. Journal of the Neurological Sciences 1988, 88:41-53.
211. Yu T., Clapcote S.J., Li Z., Liu C., Pao A., Bechard A.R., et al. Deficiencies in the region syntenic to human 21q22.3 cause cognitive deficits in mice. Mammalian Genome 2010, 21:258-267.
212. Yu T., Li Z., Jia Z., Clapcote S.J., Liu C., Li S., et al. A mouse model of Down syndrome trisomic for all human chromosome 21 syntenic regions. Human Molecular Genetics 2010, 19:2780-2791.
213. Yu T., Liu C.H., Belichenko P., Clapcote S.J., Li S.M., Pao A.N., et al. Effects of individual segmental trisomies of human chromosome 21 syntenic regions on hippocampal long-term potentiation and cognitive behaviors in mice. Brain Research 2010, 1366:162-171.
214. Yu T., Liu C.H., Belichenko P., Clapcote S.J., Li S.M., Pao A.N., et al. Effects of individual segmental trisomies of human chromosome 21 syntenic regions on hippocampal long-term potentiation and cognitive behaviors in mice. Brain Research 2010, 1366:162-171.
215. Zang D.W., Yang Q., Wang H.X., Egan G., Lopes E.C., Cheema S.S. Magnetic resonance imaging reveals neuronal degeneration in the brainstem of the superoxide dismutase 1(G93A G1H) transgenic mouse model of amyotrophic lateral sclerosis. European Journal of Neuroscience 2004, 20:1745-1751.